FARE Statement on DBV Technologies’ Complete Response Letter from FDA for Viaskin Peanut BLA

McLean, Va. (August 4, 2020)

“FARE is disappointed to learn that the FDA will not be approving DBV Technologies’ peanut allergy skin patch in its present form,” said Lisa Gable, chief executive officer of FARE. “The peanut patch represented a strong step forward for food allergy treatment at a most critical time. While today’s news is not what we had hoped, FARE supports innovation in treatments with better safety profiles and convenience factors that enable more treatment options for the full and diverse population of food allergy patients. We are confident that the concerns raised by the FDA can be addressed and that this development will lead to an improved version of the patch and ultimately provide more treatment options for not just peanut-allergic children but for all 32 million Americans living with food allergies.”